$220.8 M

ADVM Mkt cap, 23-Sept-2021

$7.5 M

Adverum Biotechnologies Revenue Q1, 2021
Adverum Biotechnologies Net income (Q1, 2021)-28.4 M
Adverum Biotechnologies EBIT (Q1, 2021)-28.6 M
Adverum Biotechnologies Cash, 31-Mar-202145.4 M
Adverum Biotechnologies EV205.6 M
Get notified regarding key financial metrics and revenue changes at Adverum BiotechnologiesLearn more
Banner background

Adverum Biotechnologies Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

572.0k2.3m1.6m250.0k

Revenue growth, %

305%(37%)

Cost of goods sold

100.0k

Gross profit

1.5m

Gross profit Margin, %

94%

R&D expense

17.0m25.5m31.7m39.8m50.1m40.4m73.3m

General and administrative expense

8.0m22.1m24.4m20.9m24.6m28.4m44.6m

Operating expense total

25.0m50.1m116.7m60.7m79.6m68.8m118.0m

EBIT

(24.4m)(47.8m)(115.3m)(58.8m)(78.1m)(68.5m)(117.9m)

EBIT margin, %

(4266%)(2062%)(4844%)(27418%)

Interest expense

18.0k370.0k762.0k2.7m

Pre tax profit

(25.4m)(47.5m)(114.5m)(56.1m)(73.9m)(64.5m)(116.4m)

Income tax expense

(775.0k)(1.2m)1.1m

Net Income

(25.4m)(47.5m)(113.7m)(56.1m)(72.6m)(64.5m)(117.5m)

Adverum Biotechnologies Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

159.4m221.3m222.2m70.5m154.9m65.9m62.4m

Prepaid Expenses

3.3m3.7m9.8m4.7m

Inventories

874.0k1.5m2.2m

Current Assets

160.3m261.0m225.3m193.7m208.8m175.9m434.4m

PP&E

1.1m3.2m4.2m3.0m3.6m24.9m27.7m

Total Assets

161.9m264.3m234.6m201.9m213.5m222.7m482.6m

Accounts Payable

951.0k605.0k1.5m1.7m1.7m4.1m2.8m

Short-term debt

4.0m4.5m

Current Liabilities

5.5m6.6m9.9m10.7m10.7m19.4m20.9m

Long-term debt

28.2m26.2m

Total Debt

32.2m30.7m

Total Liabilities

19.0m17.9m12.3m47.8m48.2m

Common Stock

5.0k6.0k7.0k10.0k

Preferred Stock

Additional Paid-in Capital

186.2m336.8m413.5m439.0m522.5m560.7m937.1m

Retained Earnings

(36.7m)(84.2m)(197.9m)(254.1m)(320.5m)(385.0m)(502.5m)

Total Equity

149.5m252.6m215.6m184.0m201.2m175.0m434.3m

Financial Leverage

1.1 x1 x1.1 x1.1 x1.1 x1.3 x1.1 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

52.4m165.3m201.8m200.5m200.7m247.1m241.3m231.3m71.6m39.5m31.7m152.7m155.5m159.7m144.1m97.8m73.2m130.2m27.4m72.7m45.4m

Accounts Receivable

8.0k8.0k1.1m1.0m1.8m

Prepaid Expenses

468.0k996.0k1.0m992.0k1.5m1.0m1.2m2.8m3.1m2.2m2.9m2.2m3.0m4.3m3.6m2.9m5.6m3.4m2.5m5.2m5.8m

Current Assets

52.9m166.3m291.1m280.6m270.4m249.2m243.6m235.9m212.6m199.6m189.5m249.2m237.9m222.2m193.1m180.6m167.6m300.4m282.7m459.7m409.9m

PP&E

509.0k817.0k1.4m2.9m3.3m3.6m4.0m4.3m4.1m3.8m3.3m2.8m2.5m2.6m4.1m6.1m15.2m26.7m27.5m27.3m28.4m

Total Assets

54.8m167.2m292.7m283.7m273.8m252.9m264.3m256.6m221.9m208.6m198.2m257.2m246.6m225.9m221.0m209.9m205.5m348.6m331.2m507.7m461.6m

Accounts Payable

1.6m1.6m2.8m1.9m1.1m486.0k2.4m3.1m3.4m1.1m1.6m685.0k2.1m1.7m1.8m740.0k3.4m4.7m10.4m3.0m2.1m

Short-term debt

4.0m4.2m4.4m4.5m

Current Liabilities

4.0m4.5m7.6m7.9m6.5m5.6m7.9m10.6m12.0m8.3m9.6m9.3m11.4m10.1m10.6m10.1m17.7m16.8m21.3m16.1m19.9m

Long-term debt

22.1m21.8m23.4m27.8m27.3m26.8m25.7m

Total Debt

22.1m21.8m23.4m31.8m31.5m31.2m30.2m

Total Liabilities

11.8m11.5m13.0m13.1m11.5m11.4m16.7m20.3m20.5m16.4m17.2m11.1m13.1m10.4m32.9m32.1m41.3m44.6m48.6m43.0m46.7m

Common Stock

2.0k3.0k3.0k3.0k3.0k4.0k4.0k4.0k5.0k5.0k7.0k6.0k6.0k6.0k6.0k7.0k8.0k8.0k10.0k10.0k

Preferred Stock

Additional Paid-in Capital

1.5m182.0m325.9m326.6m332.4m341.1m408.9m411.8m415.6m418.0m420.8m512.2m518.3m521.3m523.9m528.5m531.1m712.7m720.3m930.2m946.1m

Retained Earnings

(18.1m)(26.3m)(46.2m)(56.0m)(70.1m)(99.6m)(161.2m)(175.5m)(214.0m)(225.4m)(239.3m)(265.1m)(283.9m)(304.9m)(335.0m)(350.0m)(366.1m)(407.9m)(437.1m)(464.9m)(531.0m)

Total Equity

(16.5m)155.7m279.7m270.6m262.3m241.6m247.7m236.2m201.4m192.2m181.0m246.0m233.4m215.6m188.1m177.7m164.2m304.0m282.6m464.7m414.8m

Financial Leverage

-3.3 x1.1 x1 x1 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1 x1.1 x1 x1.2 x1.2 x1.3 x1.1 x1.2 x1.1 x1.1 x

Adverum Biotechnologies Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(25.4m)(47.5m)(113.7m)(56.1m)(72.6m)(64.5m)(117.5m)

Depreciation and Amortization

162.0k812.0k1.6m2.1m1.8m1.6m4.2m

Accounts Receivable

8.0k(44.0k)(437.0k)886.0k

Inventories

(624.0k)(531.0k)71.0k

Accounts Payable

(6.0k)18.2m(111.0k)333.0k(67.0k)(650.0k)1.6m

Cash From Operating Activities

(5.6m)(35.3m)(38.4m)(45.4m)(54.0m)(49.2m)(79.3m)

Purchases of PP&E

(943.0k)(3.0m)(2.4m)(1.0m)(809.0k)(19.2m)(11.8m)

Cash From Investing Activities

(943.0k)(41.6m)38.8m(122.2m)69.4m(68.1m)(280.2m)

Long-term Borrowings

(175.0k)(112.0k)(61.0k)

Cash From Financing Activities

165.4m138.9m556.0k16.7m69.9m28.2m356.0m

Net Change in Cash

(151.7m)85.4m(89.1m)(3.5m)

Income Taxes Paid

1.1m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(6.8m)(15.0m)(9.5m)(19.3m)(33.4m)(15.4m)(77.1m)(91.4m)(16.1m)(27.5m)(41.4m)(17.2m)(36.0m)(57.0m)(14.5m)(29.4m)(45.6m)(22.9m)(52.1m)(79.9m)(28.4m)

Depreciation and Amortization

34.0k83.0k118.0k265.0k506.0k320.0k663.0k1.1m516.0k1.1m1.6m459.0k1.1m1.4m426.0k846.0k1.2m1.2m

Accounts Receivable

(668.0k)(580.0k)(532.0k)886.0k886.0k886.0k

Accounts Payable

114.0k127.0k1.8m534.0k283.0k(140.0k)646.0k817.0k1.6m(334.0k)166.0k(1.0m)394.0k5.0k(136.0k)(924.0k)(680.0k)2.5m7.0m1.4m(763.0k)

Cash From Operating Activities

4.4m(593.0k)(7.7m)(17.0m)(26.2m)(12.2m)(20.4m)(30.0m)(11.8m)(23.2m)(33.2m)(13.0m)(24.3m)(41.2m)(13.2m)(24.8m)(34.3m)(13.6m)(30.5m)(57.1m)(22.3m)

Purchases of PP&E

(474.0k)(579.0k)(411.0k)(1.5m)(2.8m)(122.0k)(1.1m)(1.5m)(263.0k)(732.0k)(918.0k)(216.0k)(382.0k)(652.0k)(2.2m)(4.7m)(10.9m)(4.2m)(7.3m)(10.4m)(1.4m)

Cash From Investing Activities

(474.0k)(579.0k)(88.8m)(81.0m)(71.6m)37.6m40.1m39.7m(138.9m)(159.5m)(156.9m)25.4m40.3m61.4m2.7m(33.8m)(48.9m)(70.7m)(159.4m)(291.7m)6.6m

Long-term Borrowings

(88.0k)(118.0k)(28.0k)(56.0k)(84.0k)(27.0k)(29.0k)(240.0k)

Cash From Financing Activities

48.0m165.9m139.0m139.1m139.1m262.0k349.0k353.0k187.0k342.0k103.0k69.8m70.0m70.0m(370.0k)1.5m1.4m148.6m151.4m355.6m1.5m

Net Change in Cash

51.9m164.8m42.4m41.1m41.3m25.7m20.0m9.9m(150.6m)(182.6m)(190.5m)82.2m85.9m90.2m(10.8m)(57.1m)(81.8m)64.3m(38.5m)6.8m(14.2m)

Adverum Biotechnologies Ratios

USDQ2, 2014

Financial Leverage

-3.3 x

Adverum Biotechnologies Operating Metrics

FY, 2016

Patents Issued

12

Patents Pending

60

Adverum Biotechnologies Employee Rating

3.934 votes
Culture & Values
3.2
Work/Life Balance
3.5
Senior Management
3.1
Salary & Benefits
3.6
Career Opportunities
3.2
Source